| Primary |
| Drug Use For Unknown Indication |
16.8% |
| Ovarian Cancer Recurrent |
13.3% |
| Ovarian Cancer |
12.4% |
| Product Used For Unknown Indication |
11.1% |
| Prophylaxis Of Nausea And Vomiting |
6.6% |
| Cervix Carcinoma |
6.2% |
| Lung Neoplasm Malignant |
4.4% |
| Small Cell Lung Cancer Stage Unspecified |
4.4% |
| Pain |
3.4% |
| Antibiotic Therapy |
3.0% |
| Bronchial Carcinoma |
2.7% |
| Vomiting |
2.3% |
| Prophylaxis |
2.2% |
| Nausea |
2.1% |
| Small Cell Lung Cancer |
1.9% |
| Acute Myeloid Leukaemia |
1.7% |
| Neoplasm |
1.7% |
| Acute Biphenotypic Leukaemia |
1.3% |
| Ovarian Epithelial Cancer Recurrent |
1.3% |
| Small Cell Lung Cancer Recurrent |
1.3% |
|
| Death |
21.4% |
| White Blood Cell Count Decreased |
21.4% |
| Thrombocytopenia |
9.6% |
| Vomiting |
5.8% |
| Interstitial Lung Disease |
4.7% |
| Neutropenia |
4.1% |
| Sepsis |
4.1% |
| Disease Progression |
2.7% |
| Drug Ineffective |
2.7% |
| Dyspnoea |
2.5% |
| Febrile Neutropenia |
2.5% |
| Anaemia |
2.2% |
| Diarrhoea |
2.2% |
| Nausea |
2.2% |
| Pyrexia |
2.2% |
| Neutrophil Count Decreased |
1.9% |
| Pancreatitis |
1.9% |
| Platelet Count Decreased |
1.9% |
| Rash |
1.9% |
| Red Blood Cell Count Decreased |
1.9% |
|
| Secondary |
| Drug Use For Unknown Indication |
21.7% |
| Product Used For Unknown Indication |
17.2% |
| Ovarian Cancer Recurrent |
16.2% |
| Small Cell Lung Cancer Stage Unspecified |
7.6% |
| Ovarian Epithelial Cancer Recurrent |
6.1% |
| Small Cell Lung Cancer |
5.1% |
| Neoplasm |
4.0% |
| Pain |
3.0% |
| Ovarian Cancer |
2.5% |
| Prophylaxis Of Nausea And Vomiting |
2.5% |
| Neoplasm Malignant |
2.0% |
| Pneumonia |
2.0% |
| Prophylaxis |
2.0% |
| Premedication |
1.5% |
| Squamous Cell Carcinoma Of The Cervix |
1.5% |
| Adenocarcinoma |
1.0% |
| Basedow's Disease |
1.0% |
| Cervix Carcinoma |
1.0% |
| Chest Pain |
1.0% |
| Lung Neoplasm Malignant |
1.0% |
|
| White Blood Cell Count Decreased |
25.0% |
| Thrombocytopenia |
21.4% |
| Somnolence |
10.7% |
| Nausea |
7.1% |
| Sepsis |
5.4% |
| Red Blood Cell Count Decreased |
3.6% |
| Skin Ulcer |
3.6% |
| Blood Urea Increased |
1.8% |
| Bradycardia |
1.8% |
| Death |
1.8% |
| Drug Ineffective |
1.8% |
| Enterocolitis Haemorrhagic |
1.8% |
| Febrile Bone Marrow Aplasia |
1.8% |
| Febrile Neutropenia |
1.8% |
| Gastrointestinal Perforation |
1.8% |
| Ill-defined Disorder |
1.8% |
| Injection Site Swelling |
1.8% |
| Mental Status Changes |
1.8% |
| Neuropathy Peripheral |
1.8% |
| Neutrophil Count Decreased |
1.8% |
|
| Concomitant |
| Sepsis |
13.3% |
| Ovarian Cancer Recurrent |
11.6% |
| Acute Leukaemia |
9.8% |
| Product Used For Unknown Indication |
9.8% |
| Prophylaxis |
9.8% |
| Enterocolitis |
8.7% |
| Hypertension |
5.8% |
| Cancer Pain |
4.0% |
| Graft Versus Host Disease |
3.5% |
| Adenovirus Infection |
2.9% |
| Cholestasis |
2.9% |
| Cytomegalovirus Viraemia |
2.9% |
| Mineral Supplementation |
2.9% |
| Constipation |
2.3% |
| Ovarian Cancer |
2.3% |
| Anaemia Of Malignant Disease |
1.7% |
| Productive Cough |
1.7% |
| Vomiting |
1.7% |
| Cervix Cancer Metastatic |
1.2% |
| Gastritis Prophylaxis |
1.2% |
|
| Bone Marrow Failure |
20.7% |
| Sepsis |
20.7% |
| Death |
6.9% |
| Pruritus |
6.9% |
| Abdominal Pain |
3.4% |
| Aspiration |
3.4% |
| Injection Site Erythema |
3.4% |
| Interstitial Lung Disease |
3.4% |
| Migraine |
3.4% |
| Neoplasm Progression |
3.4% |
| Pneumonia |
3.4% |
| Proteinuria |
3.4% |
| Small Cell Lung Cancer Metastatic |
3.4% |
| Streptococcal Bacteraemia |
3.4% |
| Thrombocytopenia |
3.4% |
| Vomiting |
3.4% |
| White Blood Cell Count Decreased |
3.4% |
|
